Mylan stock dropped 7% after second quarter sales slumped (MYL)

• Mylan’s stock dropped 7.4% shortly after markets opened on Wednesday due to poor second quarter earnings.
• The company’s total revenue for the second quarter was $2.8 billion, down 5% compared to last year. Sales in North America also fell 22%. 
• Mylan then announced that it was going to conduct a strategic review of the company, saying it believes it is undervalued. This means the company could be broken up or sold. 
• Mylan N.V. is an American pharmaceutical company registered in the Netherlands that makes both generic and specialty drugs. It is best known as the manufacturer of EpiPen. 

Join the conversation about this story »

NOW WATCH: Stock trading is a ‘monotheistic religion’ — a JPMorgan chief strategist reveals the one thing that will keep the market soaring